Medicine questions
Liraglutide: which version is being offered?
The word generic can leave an important question unanswered. Ask what product it is a generic version of.
A generic is a version of a brand medicine approved by FDA, short for Food and Drug Administration.
| The name in the offer | The distinction to check |
|---|---|
| Liraglutide (Victoza, Saxenda) Liraglutide copies the action of a gut hormone, a chemical messenger linked to appetite and blood sugar. | The intended use Victoza has a type 2 diabetes use; Saxenda has a weight-management use. |
| Generic liraglutide FDA-approved generics exist for both the Victoza-type and Saxenda-type products. | The generic type The diabetes and weight-management groups are not interchangeable at the pharmacy. |
| A supply plan Ask what will happen if the specific product cannot be filled. | Approval versus stock A generic approval does not confirm that the product is on a pharmacy shelf. |
Ask about continuity before starting
As of September 26, 2026, the maker planned the last Saxenda shipments to wholesalers for late January 2027.
The maker said it was ending the brand as use declined, rather than because of safety or quality concerns.
Wholesalers are the businesses that supply pharmacies. Ask which exact product is proposed and how the clinician would handle a change in supply. Keep the answer separate from any promise about a generic being available nearby.
What the main weight trial found
A trial compares treatments in a group of people. The dummy injection provides a comparison without the study medicine.
The SCALE weight trial studied adults without diabetes for 56 weeks. The liraglutide group’s average loss came to 8.4 kilograms (about 18.5 pounds); with dummy injections, the average was 2.8 kilograms (about 6.2 pounds).
The trial reported weights in kilograms; the pounds shown here give the same amounts. Ask the clinician to explain what the trial does and does not say about your own goals.
In Saxenda adult trials, nausea affected 39.3% on the medicine versus 13.8% on a dummy injection.
Nausea is the feeling that you may vomit.
Do not skip the label discussion
The liraglutide label’s boxed warning, its strongest alert, describes thyroid tumors in rodents; whether the same happens in humans is unknown.
The labels exclude use after medullary thyroid cancer in either the patient or a family member; this is a rare thyroid cancer. They also rule out the medicine for MEN 2, an inherited condition that is rare.
A serious allergic reaction to liraglutide or its ingredients also rules it out under the labels.